These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 16888761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS.
    Cancer Chemother Pharmacol; 2003 Apr 01; 51(4):297-305. PubMed ID: 12721757
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC.
    Cancer; 2003 Oct 15; 98(8):1603-10. PubMed ID: 14534875
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
    Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW.
    BJU Int; 2008 Dec 15; 102(11):1601-6. PubMed ID: 18782306
    [Abstract] [Full Text] [Related]

  • 6. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
    Sheen WC, Chen JS, Wang HM, Yang TS, Liaw CC, Lin YC.
    Jpn J Clin Oncol; 2004 Jun 07; 34(6):337-41. PubMed ID: 15333686
    [Abstract] [Full Text] [Related]

  • 11. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC, Hsu CH, Chen J, Tsai TC, Cheng AL, Pu YS.
    Anticancer Res; 2001 Jun 07; 21(2B):1385-90. PubMed ID: 11396219
    [Abstract] [Full Text] [Related]

  • 12. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V, Breast Cancer Committee of the Hellenic Oncology Research Group.
    Cancer Chemother Pharmacol; 2006 Dec 07; 58(6):742-8. PubMed ID: 16718470
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P, Velasco A, Bolaños M, del Mar Perez M, Mel JR, Reina JJ, Rodríguez-Jaraiz MA, Chaves M, González-Barón M.
    Urol Oncol; 2004 Dec 07; 22(1):32-5. PubMed ID: 14969801
    [Abstract] [Full Text] [Related]

  • 14. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 15. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
    Bernardi D, Talamini R, Zanetti M, Simonelli C, Vaccher E, Spina M, Tirelli U.
    Prostate Cancer Prostatic Dis; 2004 Jun 15; 7(1):45-9. PubMed ID: 14999238
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W.
    J Clin Oncol; 2003 Sep 01; 21(17):3335-42. PubMed ID: 12947070
    [Abstract] [Full Text] [Related]

  • 17. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, Fornetti P, Porena M.
    Cancer; 2000 Mar 15; 88(6):1438-44. PubMed ID: 10717628
    [Abstract] [Full Text] [Related]

  • 18. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ.
    J Urol; 2002 Aug 15; 168(2):542-5. PubMed ID: 12131305
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
    Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI.
    J Urol; 2007 Dec 15; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.